Form 4: Dyne Therapeutics Chief Scientific Officer Acquires Shares and Options

Dyne Therapeutics' Chief Scientific Officer, Oxana Beskrovnaya, acquired shares and stock options, increasing her beneficial ownership in the company.

Summary

• Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, has reported changes in her beneficial ownership of the company's stock.
• On December 4, 2024, she acquired 39,100 shares of common stock through restricted stock units (RSUs) that vest quarterly over four years starting March 4, 2025.
• She also acquired 27,400 shares of common stock through RSUs that vest in full on December 4, 2025.
• Additionally, she was granted a stock option to purchase 62,400 shares of common stock at an exercise price of $29.44, vesting monthly over four years through December 4, 2028.
• Following these transactions, Ms. Beskrovnaya's total beneficial ownership includes 204,019 shares of common stock and options for 62,400 shares.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the increase in executive ownership is generally viewed positively by investors.

Positives

• The acquisition of shares and options by a key executive like the Chief Scientific Officer can be seen as a positive sign of confidence in the company's future prospects.
• The vesting schedules of the RSUs and stock options align the executive's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The vesting schedules for the RSUs and stock options are typical for executive compensation packages in the biotechnology industry.
• The use of both RSUs and stock options is a common practice to incentivize long-term performance and align executive interests with shareholder value.
• Similar filings are regularly made by executives at comparable companies such as Sarepta Therapeutics and BioMarin Pharmaceutical.

Stakeholder Impact

• The increased ownership by the Chief Scientific Officer may be viewed positively by shareholders, indicating confidence in the company's future.
• Employees may see this as a positive sign of leadership commitment.

Key Dates

Keywords

Dyne Therapeutics, Oxana Beskrovnaya, stock options, restricted stock units, beneficial ownership, insider trading, executive compensation